Compare Equinix Inc (EQIX) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinix Inc vs Johnson & Johnson — how do they compare? Equinix Inc trades at $1,025.96 (market cap $99.77B), while Johnson & Johnson trades at $260.64 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 6.2× Equinix Inc's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Equinix Inc for 110 Days and Johnson & Johnson for 129 Days on average.
| EQIX | JNJ | |
|---|---|---|
Market Cap | $99.77B | $618.09B |
Volume | 480,425 | 6,050,983 |
Sector | Real Estate | Health |
52-Week High | $1.12K | $278.43 |
52-Week Low | $726.09 | $186.00 |
Typical Hold Time | 110 Days | 129 Days |
Enterprise Value | $120.90B | $646.37B |
Dividend Yield | 2.04% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinix (EQIX) trades at $1,019.70, down 1.17% on the day, with a bearish technical signal and mixed earnings history including a recent Q2 2026 beat. The company shows strong revenue growth, reaching $9.22B in 2025, and a net income margin of 15.63%, but faces high valuation ratios like a P/E of 65.07. Recent news highlights AI-driven data center demand and a $5B-$7B annual buildout plan, supporting long-term growth prospects amid significant capital expenditures.
The outlook for EQIX is cautiously optimistic, with Wall Street analysts largely bullish (75% buy ratings) and a consensus price target of $1,250 offering ~22% upside. Key risks include elevated debt levels, with debt-to-asset ratio rising to 47.13% in 2025, and sustained negative cash flow from aggressive expansion investments. Investors should weigh strong AI-driven demand against execution risks and high valuation multiples.
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
